CXCR2 Leucocyte Expression Level as a Predictive Factor of Coronary Artery Calcification Progression in Advanced Chronic Kidney Disease Patients

NCT07811505 | Not Yet Recruiting

• 1 other identifier: PI2026_843_0037
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic kidney disease (CKD) is associated with the development of coronary arteries calcifications (CAC) and increased cardiovascular mortality. Previously, the investigators demonstrated that interleukin 8 (IL-8) plays a role in the calcification process, and that blockade of its receptor, CXCR2 reduces cardiovascular calcifications. The investigators hypothesize that leucocytes expressing CXCR2 may contribute to the development and progression of CAC in CKD patients. Identifying CKD patients with a high calcification phenotype and therapeutic targets to prevent cardiovascular calcifications is essential. Advanced CKD patients (stages IV and V) will undergo analysis of CXCR2 expression from neutrophils and monocytes at inclusion by flow cytometry, followed by non-contrast thoracic CT scans at inclusion, 1 year and 3 years to assess calcification scores and progression. Patients will have a pre-inclusion visit for research information and consent. If consent is given, three protocol visits (inclusion, 1 year, 3 years) including clinical exam, laboratory tests and CT evaluations will be performed.

Conditions

Chronic Kidney Disease; Coronary Arteries Calcifications; CXCR2 Expression

Keywords

chronic kidney disease; coronary arteries calcifications; CXCR2 expression

Outcome Measures

Primary Outcomes (2)

• variation from baseline of CXCR2 expression

  CXCR2 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells) from blood sample.

  at 3 years

• Correlation between CXCR2 expression and calcium score

  The coronary calcification score will be determined by Agatston method. CXCR2 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells) from blood sample.

  at 3 years

Secondary Outcomes (8)

• CXCR2 expression and the 1-year progression of the calcium score

  at 1 year

• Correlation between CXCR1 or CXCR2 expression and calcium score trajectory

  1 year

• Correlation between CXCR2 expression and the calcium score progression in other vascular territories

  at 3 years

• Correlation between CXCR1 expression and the calcium score progression in other vascular territories

  at 3 years

• Correlation between a CXCR1- or CXCR2-positive leukocyte phenotype and CKD progression

  at 3 years

Study Arms (1)

CKD patients

EXPERIMENTAL

Other: Thoracic CT; Biological: Blood samples

Interventions

Thoracic CT OTHER

Thoracic CT will be performed at inclusion, 1 year and 3 years to assess coronary calcification and aortic valve calcification scores and progression.

CKD patients

Blood samples BIOLOGICAL

Blood samples will be collected at inclusion, 1 year and 3 years to measure CXCR1 and CXR2 expression on neutrophils and monocytes by flow cytometry.

CKD patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• age \> 18 years
• CKD defined by eGFR \< 30 mL/min/1,73m²
• signed inform consent

You may not qualify if:

• patients on dialysis,
• kidney transplant recipients,
• current or recent (within 30 days) infection,
• inflammatory diseases,
• active cancer treatment,
• use of immunosuppressive agents,
• presence of coronary stents or aortic valve protheses,
• inability to provide informed consent.

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHRU Amiens

Amiens, 80480, France

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Quentin DE BERNY, MD

CONTACT

33+3 22 45 58 62; deberny.quentin@chu-amiens.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 23, 2026
• First Posted: September 10, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): August 1, 2029
• Study Completion (Estimated): August 1, 2031
• Last Updated: September 10, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)